Literature DB >> 12234456

A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.

Carole Cummins1, M Connock, A Fry-Smith, A Burls.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12234456     DOI： 10.3310/hta6170

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN： 1366-5278            Impact factor:   4.014


× No keyword cloud information.
  10 in total

Review 1.  The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication.

Authors:  Wendy Gidman; Rachel Meacock; Deborah Symmons
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

2.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

4.  Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked.

Authors:  Femke H M Prince; Lisette W A van Suijlekom-Smit
Journal:  Paediatr Drugs       Date:  2013-08       Impact factor: 3.022

Review 5.  Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

6.  Expediting systematic reviews: methods and implications of rapid reviews.

Authors:  Rebecca Ganann; Donna Ciliska; Helen Thomas
Journal:  Implement Sci       Date:  2010-07-19       Impact factor: 7.327

7.  Burden and cost of illness in patients with juvenile idiopathic arthritis.

Authors:  K Minden; M Niewerth; J Listing; T Biedermann; M Schöntube; A Zink
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

Review 8.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

9.  Socioeconomic costs and health-related quality of life in juvenile idiopathic arthritis: a cost-of-illness study in the United Kingdom.

Authors:  Aris Angelis; Panos Kanavos; Julio López-Bastida; Renata Linertová; Pedro Serrano-Aguilar
Journal:  BMC Musculoskelet Disord       Date:  2016-08-02       Impact factor: 2.362

10.  Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis.

Authors:  J Thornton; M Lunt; D M Ashcroft; E Baildam; H Foster; J Davidson; J Gardner-Medwin; M W Beresford; D Symmons; W Thomson; R A Elliott
Journal:  Rheumatology (Oxford)       Date:  2008-04-16       Impact factor: 7.580
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.